title: Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy.
abstract: Cytotoxic T lymphocytes (CTL) and highly active antiretroviral therapy (HAART) are known to exert strong evolutionary pressures on the virus population during human immunodeficiency virus (HIV) infection. However, it is not known whether CTL responses continue to substantially affect viral evolution during treatment. To study the effect of immunologic pressure on viral sequences during HAART, we identified 10 targeted HIV-specific CD8+-T-cell epitopes in five treatment-naive patients, sequenced each epitope in plasma-derived viruses, and then identified evidence of immunologic pressure at these epitopes by comparing the frequency of viral variants in plasma to the frequency of the CD8+-T-cell response for each variant identified. For one of the five patients, evidence of viral evolution was found during therapy. The sequence of the CTL-targeted epitope changed from an apparent escape variant prior to the initiation of therapy, to the sequence that is best recognized by the CTL response after the initiation of therapy, and then finally to a new escape variant during continued therapy. These data show that CTL-mediated pressure can continue to affect viral evolution after the initiation of HAART, even when treatment drives the viral load below detectable levels, and suggest that antiretroviral therapy may preferentially inhibit those virus variants that escape the CTL response.
authors.affiliation: Immunology Laboratory, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Casazza
authors.forename: Michael R
authors.initials: MR
authors.lastname: Betts
authors.forename: Brenna J
authors.initials: BJ
authors.lastname: Hill
authors.forename: Jason M
authors.initials: JM
authors.lastname: Brenchley
authors.forename: David A
authors.initials: DA
authors.lastname: Price
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Douek
authors.forename: Richard A
authors.initials: RA
authors.lastname: Koup
mesh_terms: D019943:Amino Acid Substitution; D023241:Antiretroviral Therapy, Highly Active; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology; D019143:Evolution, Molecular; D006678:HIV / Q000187:drug effects / Q000235:genetics* / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D020125:Mutation, Missense; D012641:Selection, Genetic; D017422:Sequence Analysis, DNA; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D018984:Epitopes, T-Lymphocyte; D015488:HIV Antigens; D006680:HLA Antigens
references.citation: J Gen Virol. 1997 Jul;78 ( Pt 7):1511-9
references.pmid: 9225023
references.citation: N Engl J Med. 1999 May 27;340(21):1614-22
references.pmid: 10341273
references.citation: J Exp Med. 1996 Apr 1;183(4):1917-21
references.pmid: 8666949
references.citation: J Exp Med. 1999 Mar 15;189(6):991-8
references.pmid: 10075982
references.citation: J Exp Med. 2001 Feb 5;193(3):375-86
references.pmid: 11157057
references.citation: J Virol. 2002 Sep;76(17):8690-701
references.pmid: 12163589
references.citation: J Virol. 2003 Jul;77(13):7330-40
references.pmid: 12805431
references.citation: Nucleic Acids Res. 2003 Jan 1;31(1):298-303
references.pmid: 12520007
references.citation: J Virol. 2001 Jul;75(14):6508-16
references.pmid: 11413318
references.citation: Nature. 2000 Sep 28;407(6803):523-6
references.pmid: 11029005
references.citation: Nat Med. 1999 Nov;5(11):1270-6
references.pmid: 10545993
references.citation: Curr Protoc Immunol. 2003 Nov;Chapter 18:Unit 18.11
references.pmid: 18432904
references.citation: J Virol. 2002 Sep;76(18):9481-92
references.pmid: 12186930
references.citation: Nature. 1998 Dec 17;396(6712):690-5
references.pmid: 9872319
references.citation: J Clin Invest. 1999 Sep;104(6):R13-8
references.pmid: 10491418
references.citation: J Virol. 1999 Jan;73(1):797-800
references.pmid: 9847391
references.citation: J Virol. 1994 Sep;68(9):6103-10
references.pmid: 8057491
references.citation: N Engl J Med. 1981 Dec 10;305(24):1431-8
references.pmid: 6975437
references.citation: Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1890-5
references.pmid: 9050875
references.citation: JAMA. 2001 Jul 11;286(2):171-9
references.pmid: 11448280
references.citation: J Clin Invest. 2002 Nov;110(9):1339-47
references.pmid: 12417573
references.citation: Virology. 2002 Oct 25;302(2):393-404
references.pmid: 12441083
references.citation: Immunogenetics. 1985;21(3):235-46
references.pmid: 3872841
references.citation: J Virol. 1999 Nov;73(11):9404-12
references.pmid: 10516049
references.citation: Nat Med. 2000 Jan;6(1):82-5
references.pmid: 10613829
references.citation: N Engl J Med. 1981 Dec 10;305(24):1425-31
references.pmid: 6272109
references.citation: Tissue Antigens. 1995 Feb;45(2):81-90
references.pmid: 7792765
references.citation: J Virol. 2002 Oct;76(20):10169-76
references.pmid: 12239291
references.citation: Nat Med. 1995 Apr;1(4):330-6
references.pmid: 7585062
references.citation: Science. 1999 Feb 5;283(5403):857-60
references.pmid: 9933172
references.citation: J Clin Invest. 1997 Feb 15;99(4):752-62
references.pmid: 9045880
references.citation: J Immunol. 2003 Jul 1;171(1):477-88
references.pmid: 12817033
references.citation: N Engl J Med. 1999 May 27;340(21):1605-13
references.pmid: 10341272
references.citation: Top HIV Med. 2003 Nov-Dec;11(6):215-21
references.pmid: 14724329
references.citation: Nature. 1994 Aug 11;370(6489):463-7
references.pmid: 8047166
references.citation: JAMA. 2001 Jul 11;286(2):196-207
references.pmid: 11448283
references.citation: Nature. 1997 May 8;387(6629):188-91
references.pmid: 9144290
references.citation: Science. 1996 Mar 15;271(5255):1582-6
references.pmid: 8599114
references.citation: Nat Med. 1998 Aug;4(8):975-8
references.pmid: 9701254
references.citation: Annu Rev Immunol. 1997;15:271-96
references.pmid: 9143689
references.citation: J Virol. 2002 Nov;76(21):10674-84
references.pmid: 12368309
references.citation: Nat Med. 1997 Feb;3(2):212-7
references.pmid: 9018241
references.citation: AIDS. 1999 Sep 10;13(13):1687-95
references.pmid: 10509570
references.citation: Science. 2000 Oct 20;290(5491):486-92
references.pmid: 11039923
references.citation: J Virol. 2004 Jul;78(13):7069-78
references.pmid: 15194783
references.citation: J Virol. 2000 Nov;74(22):10269-73
references.pmid: 11044070
references.citation: J Virol. 1994 Jul;68(7):4650-5
references.pmid: 8207839
references.citation: J Virol. 1996 Aug;70(8):5720-30
references.pmid: 8764096
references.citation: Nat Med. 1997 Feb;3(2):205-11
references.pmid: 9018240
references.citation: Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8
references.pmid: 8990195
references.citation: Science. 2002 May 24;296(5572):1439-43
references.pmid: 12029127